Odonate Therapeutics (ODT) Short Interest Ratio & Short Volume

Short interest is the volume of Odonate Therapeutics shares that have been sold short but have not yet been closed out or covered. As of December 31st, investors have sold 379,600 shares of ODT short. 1.22% of Odonate Therapeutics' shares are currently sold short. Learn More on Odonate Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.22% of Odonate Therapeutics' floating shares are currently sold short.

Odonate Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totaling 379,600 shares, a decline of 35.8% from the previous total of 591,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Odonate Therapeutics currently has issued a total of 28,530,000 shares. Some of Odonate Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Odonate Therapeutics currently has a public float of 31,160,000 shares.

1.22% of Odonate Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Odonate Therapeutics: Context Therapeutics Inc. (0.08%), Grifols, S.A. (2.32%), LAVA Therapeutics (1.50%), Mainz Biomed (2.34%), NLS Pharmaceutics Ltd. (1.54%), Pharvaris (0.10%), Procaps Group S.A. (0.03%), Qilian International Holding Group Limited (0.07%), American Oncology Network, Inc. (1.02%), Mirum Pharmaceuticals, Inc. (17.36%), and

As of the most recent reporting period, the following stocks had the largest short interest positions: S&P Global Inc. ($9.39 billion), Advanced Micro Devices, Inc. ($9.08 billion), Charter Communications, Inc. ($7.16 billion), Palo Alto Networks, Inc. ($4.05 billion), Lucid Group, Inc. ($3.43 billion), Wayfair Inc. ($3.11 billion), Rivian Automotive, Inc. ($3.05 billion), Datadog, Inc. ($2.76 billion), Zscaler, Inc. ($2.55 billion), and Etsy, Inc. ($1.99 billion). View all of the most shorted stocks.

Short selling ODT is an investing strategy that aims to generate trading profit from Odonate Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Odonate Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ODT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ODT, twice per month. The most recent reporting period available is December, 31 2021.